NIH finds new bladder cancer targets

Share this article:

The Cancer Genome Atlas Research Network, a collaboration between two National Institutes of Health groups, has identified new drug targets for bladder cancer that invades the bladder's muscle, a condition the group notes is the deadliest form of the disease, and for which there is no approved second-line therapy.

Researchers also found that the cancer has some genetics in common with some breast, lung, and head & neck cancers, which could help identify new ways to approach the disease.

Among the findings: 

  • Recurrent mutations in 32 genes, nine of which were not previously known to be “significantly mutated"
  • Potential drug targets in 69% of the evaluated tumors
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.